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unresectable high-grade osteosarcoma and
spindle cell sarcoma of bone
E. Palmerini1,9*, R. L. Jones2, E. Marchesi1, A. Paioli1, M. Cesari1, A. Longhi1, C. Meazza3, L. Coccoli4, F. Fagioli5,
S. Asaftei5, G. Grignani6, A. Tamburini7, S. M. Pollack2, P. Picci8 and S. Ferrari1
Abstract
Background: Few new compounds are available for relapsed osteosarcoma. We retrospectively evaluated the
activity of gemcitabine (G) plus docetaxel (D) in patients with relapsed high-grade osteosarcoma and high-grade
spindle cell sarcoma of bone (HGS).
Methods: Patients receiving G 900 mg/m2 d 1, 8; D 75 mg/m2 d 8, every 21 days were eligible. Primary end-point:
progression-free survival (PFS) at 4 months; secondary end-point: overall survival (OS) and response rate.
Results: Fifty-one patients were included, with a median age of 17 years (8–71), 26 (51 %) were pediatric patients.
GD line of treatment: 2nd in 14 patients, ≥3rd in 37. 25 (49 %) patients had metastases limited to lungs, 26 (51 %)
multiple sites. Histology: 40 (78 %) osteosarcoma, 11 (22 %) HGS. Eight (16 %) patients achieved surgical complete
response (sCR2) after GD.
Four-month PFS rate was 46 %, and significantly better for patients with ECOG 0 (ECOG 0: 54 % vs ECOG 1: 43 % vs
ECOG 2: 0 %; p = 0.003), for patients undergoing metastasectomy after GD (sCR2 75 % vs no-sCR2 40 %, p = 0.02)
and for osteosarcoma (osteosarcoma 56 % vs HGS 18 %; p = 0.05), with no differences according to age, line of
treatment, and pattern of metastases.
Forty-six cases had RECIST measurable disease: 6 (13 %) patients had a partial response (PR), 20 (43 %) had stable
disease (SD) and 20 (43 %) had progressive disease (PD).
The 1-year OS was 30 %: 67 % for PR, 54 % for SD and 20 % for PD (p = 0.005).
Conclusions: GD is an active treatment for relapsed high-grade osteosarcoma, especially for ECOG 0 patients, and
should be included in the therapeutic armamentarium of metastatic osteosarcoma.
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Background
At present, patients with nonmetastatic osteosarcoma of
the extremity under the age of 40 years, have an ex-
pected 5-year survival rate of 70 % with multi-modality
management consisting of chemotherapy (based on
methotrexate, cisplatin, doxorubicin and ifosfamide) and
surgery [1, 2].
While the outcome of patients with localized osteosar-
coma of bone has improved with the introduction of
multi-agent chemotherapy in combination with surgery
[1, 2], treatment options for patients with relapsed dis-
ease are limited and post-relapse survival is poor, with a
5-year post relapse survival (PR) rate below 30 % [3].
The role of second-line chemotherapy for recurrent
osteosarcoma is much less well defined, and there is no
accepted standard regimen. Treatment choice may take
into account the prior disease-free interval, and often in-
cludes ifosfamide ± etoposide ± carboplatin, and other ac-
tive drugs [4].
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High-dose ifosfamide (HDIFO) has been widely used
for patients with metastatic osteosarcoma [5, 6], but, no
new drugs were FDA or EMA approved over the last
25 years.
Prospective trials with agents such as pemetrexed or so-
rafenib and sorafenib/everolimus were performed [7–9].
Some of these agents have shown modest activity in osteo-
sarcoma, but none were deemed worthy of further
development.
In general, there are few indications for radiation ther-
apy, but there are anatomical locations in which the pos-
sibility of complete surgical resection is limited. In these
cases, radiation may be an option to try to extend the
progression-free interval. Novel local treatment tech-
niques (e.g. proton beam therapy, radiofrequency abla-
tion and isolated limb perfusion) may have a role in
specific patients, under the management of a multi dis-
ciplinary team [4].
The combination of gemcitabine (G) plus docetaxel (D)
is active in soft tissue sarcomas, with published data indi-
cating higher activity than gemcitabine alone [10–12].
Although the biology of soft tissue sarcomas is fundamen-
tally different from that of bone sarcoma, the efficacy of
these two drugs has also been investigated in patients with
recurrent osteosarcoma with conflicting results (Table 1;
[13–18]).
Here we report the results of a retrospective multicen-
ter analysis of the activity of this combination in patients
with recurrent high-grade osteosarcoma and high-grade
spindle cell sarcoma of bone (HGS).
This analysis involves both pediatric and adult pa-
tients, primarily as management for patients with local-
ized disease is the same, regardless of age.
Methods
A joint analysis between the Italian Sarcoma Group and
the Sarcoma Center of the University of Washington
was planned, in order to collect data on patients with
metastatic high grade bone sarcomas treated with GD.
This study was approved by the ethics committees of
all 6 centers participating to the study: 5 Italian referral
centers (Rizzoli Institute, Bologna; Tumor National
Institute, Milan; Pediatric Oncology Departments of
Turin; Meyer Children’s Hospital, Florence; Pediatric
Onco-Hematology, Pisa) and the Sarcoma Center of the
University of Washington.
All patients included in the study signed informed
consent for treatment and privacy according to each in-
dividual institution’s requirements.
The analysis period was set from January 2012 and
August 2014.
Patients with the following characteristics were in-
cluded: 1) diagnosis of high-grade osteosarcoma and
spindle cell sarcoma of bone, 2) recurrent or advanced
disease not amenable of surgical treatment, 3) disease
progression after at least one line of chemotherapy, 4)
treatment with GD, 5) availability of demographic, clin-
ical and follow-up data. The following were required for
cases evaluable for response 1) treated with at least 2 cy-
cles of GD, 2) having measurable disease as per RECIST
1.1 and 3) with radiological images for review.
The diagnosis was confirmed in all cases by an experi-
enced bone sarcoma pathologist.
Drugs were administered as follows: G 675–900 mg/m2
over 90 min on Day 1 and G 675–900 mg/m2 and D
75 mg/m2 on Day 8. All patients received pre-medication
with steroids prior to docetaxel.
Patient characteristics including age, gender, ECOG
performance status, primary tumor site, site and number
of metastatic lesions, type and number of prior treat-
ments, response to therapy, toxicity, date of progression,
date of last follow-up or death were obtained from the
databases or the patient clinical chart and collected in a
study-specific case report form.
All relevant radiological images we re-reviewed for the
purpose of this study (EP, RLJ). Response was assessed
using the Response Evaluation Criteria In Solid Tumors
(RECIST) version 1.1. Patients were assessed for re-
sponse after the first 2 cycles and, in case of response or
stable disease, every 2 or 3 cycles of therapy. Objective
response was expressed as response rate (complete re-
sponse [CR] + partial response [PR]), stable disease (SD)
or progressive disease (PD).
Toxicity data were collected from clinical chart and
from “patient-toxicity” questionnaires, in some of the
centers. Toxicity was graded according to the Common
Table 1 Gemcitabine and docetaxel in advanced osteosarcoma
Drugs Pts n. RR CR/PR Authors
G 1,000 mg/m2 7 0 % 0/0 Merimsky O, Sarcoma 2000 [13]
G 675 mg/m2 D 75–100 mg/m2 10 30 % 0/3 Navid F, Cancer 2008 [14]
G 900 mg/m2 D 80–100 mg/m2 14 7 % 0/1 Fox E. SARC 003, Oncologist 2010 [15]
G 675 mg/m2 ± D 75–100 mg/m2 4 25 % 0/1 Gosiengfiao Y, J Pediatr Hematol Oncol 2012 [16]
G 675 mg/m2 + D 75–100 mg/m2 18 5 % 0/1 Qi WX, Jpn J Clin Oncol 2012 [17]
G 675–900 mg/m2 D 100 mg/m2 17 24 % 3/1 Song BS, Pediatr Blood Cancer 2014 [18]
GD gemcitabine and docetaxel, RR response rate, CR complete response, PR partial response
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Toxicity Criteria for Adverse Events (CTCAE) version 4.
In case of grade 4 neutropenia prophylactic use of G-
CSF was allowed; therapeutic use of G-CSF was
mandatory in case of febrile neutropenia.
Treatment was discontinued at progression or un-
acceptable toxicity. All patients who received at least
one cycle (one cycle was defined as G on Day 1 and GD
on Day 8, every 21 days) were included in an intention-
to-treat analysis.
Progression-Free Survival (PFS) and Overall Survival
(OS), were estimated according to the Kaplan and Meier
method with their respective 95 % confidence intervals
(CI) and calculated from the first day of chemotherapy
administration to tumor progression (PFS) or death or
last follow-up visit (OS).
Metastasectomy was performed on a “case-by-case”
basis, following multidisciplinary discussion. Only patients
with confirmed response (partial response or stable dis-
ease after 2 consecutive assessments) were considered for
surgical removal of metastases. If excision of all secondary
lesions became possible, patients were classified as achiev-
ing a second surgical complete remission (sCR2).
Results
Fifty-one patients were included in the study. The clin-
ical characteristics are shown in Table 2. Twenty-six pa-
tients (51 %) were aged less than 18 years. Most of the
patients had an ECOG performance status of 0 and 73 %
had received 1 or more chemotherapy lines (with a max-
imum of 5 lines). 40 (78 %) patients had high-grade
osteosarcoma and 11 (22 %) had HGS. The median age
was 17 years (range 8 to 71 years): 14.5 years (range 8 to
59) for osteosarcoma patients and 36 years (range 18 to
71) for the 11 patients with HGS.
All patients had received neoadjuvant/adjuvant chemo-
therapy with doxorubicin (cumulative dose 360–
420 mg/m2), cisplatin (600 mg/m2), ifosfamide (30–60
gr/m2), while methotrexate (36–60 gr/m2), was ad-
ministered to all patients younger than 40 years.
Fourteen (27 %) patients received GD at their first re-
currence. Thirty-seven patients received GD combination
after failure of prior chemotherapy lines (with a maximum
of 5 lines) (Table 2). HDIFO (ifosfamide 15 g/m2 plus
mesna as a 5 day-continuous infusion or 14 gr/m2 in
14 day-continuous infusion) was offered to all cases prior
to GD: in 1st line, or in the adjuvant setting in case of
poor response to neoadjuvant chemotherapy. Other drugs
employed in the metastatic setting were: cyclophospha-
mide and etoposide, ifosfamide and etoposide, sorafenib,
sorafenib and everolimus, pemetrexed, vinorelbine and
anti IGF-1R based therapies.
The schedule of gemcitabine at a lower dose (675 mg/m2)
was employed in 8 cases, mainly in pediatric patients.
Response assessment
Five patients were excluded from the response evalu-
ation: two patients did not receive docetaxel due to an
allergic reaction, one for grade 4 skin toxicity after the
first cycle and 2 patients with metastatic lesions that
were non measurable by RECIST.
In 46 patients evaluable for response: 6 patients
achieved a PR (6/46 [13 %]) and 20 (43 %) SD, with a me-
dian duration of response lasting 6.5 months (range 2–11)
for PRs and 4 months (range 2 to 16 months), for patients
with SD. All patients achieving a partial response had clas-
sic osteosarcoma histology, and 5 of them were pediatric.
Twenty out of 46 patients experienced progressive disease
(PD) (20/46, 43 %) (Fig. 1, Table 3).
Toxicity
The safety analysis is based on the 51 patients who re-
ceived at least one dose of chemotherapy. The median
number of cycles administered was 4 (range 1–20 cycles).
Grade 4 hematological toxicity was observed in 13
Table 2 Clinical, Pathologic and Treatment Variable patients
with osteosarcoma and high grade spindle cell sarcoma of
bone
Characteristics Pts n. %
Histology
Osteosarcoma 40 78 %
HGS 11 22 %
Gender
Male 36 70 %
Female 15 30 %
Age
≥18 years 25 49 %
<18 years 26 51 %
ECOG
0 33 64 %
1 14 28 %
2 4 8 %
Line of CT for metastases
1 14 27 %
2 28 55 %
≥3 9 18 %
Pattern of metastases
Lung Only 25 49 %
Multiple 26 51 %
Bone metastases
Yes 13 25 %
No 38 75 %
HGS High grade spindle cell sarcoma of bone, GD gemcitabine and docetaxel,
CT chemotherapy
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Fig. 1 RECIST responses by chest CT scan in 3 patients with bilateral lung metastases, before gemcitabine and docetaxel (GD) treatment (a, b, c)
and after 2 cycles of therapy (e, f, g); PET/CT imaging showing 18 F-FDG uptake in a patient with osteosarcoma lung metastastases, before GD
treatment (d) and after 7 cycles of therapy (h)
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(25 %) patients, with 11 (21 %) experiencing grade 4
neutropenia and two grade 4 thrombocytopenia. Non-
hematological toxicity was reported in 8 (16 %) patients,
with 3 (6 %) patients experiencing allergic reactions (two
following the first cycle and one after 4 cycles). Diarrhea
(grade 1) was reported in 2 cases, lung fibrosis, Steven
Johnson syndrome and capillary leak syndrome in one
patient each (Table 4).




The median PFS was 3.5 months (range 1–13.5 months).
The 4- and 6-month PFS were 46 % (95 % CI; 31–61 %)
and 28 % (95 % CI, 15–42), respectively (Fig. 2a, Table 5).
The 4-month PFS was significantly better for patients
with osteosarcoma compared to HGS (Fig. 2b). No sig-
nificant difference was observed according to age, gen-
der, number of lines of systemic therapy and pattern of
metastatic spread. Patients with a good performance sta-
tus (ECOG 0) had significantly better PFS (Table 5).
Overall survival post GD
The median survival time post gemcitabine plus doce-
taxel was 7.5 months (range 2–45 months).
The 1-year overall survival was 30 % (95 % CI; 22–57).
For patients achieving a PR the 1-year OS was 67 % (95 %
CI; 13–100), for those with SD it was 54 % (95 % CI;
25–85), and for those with PD 20 % (95 % CI; 10–
38) (p = 0.005).
Following GD, 8 patients underwent surgery and
achieved a surgical complete response (sCR2). Six of
these patients had lung metastases, 1 had a gastric lesion
and another patient had a local recurrence with a syn-
chronous subcutaneous metastasis. All these patients
had osteosarcoma and the median age was 14.5 years
(range 11–23 years). The 4-month PFS for patients
achieving sCR2 was 75 % (95 % CI; 45–100), and 49 %
(95 % CI; 24–56) for the others, p = 0.02 (Fig. 3).
Discussion
Our multi-institutional retrospective study evaluated the
activity of GD in a group of heavily pretreated patients
with high grade osteosarcomas and HGS.
Our study demonstrated a 4-month PFS of 46 %, with
better PFS in patients with a good performance status.
Also, histology seems an important predictor of re-
sponse, with a 4-month PFS of 56 % in patients with
classic high-grade osteosarcoma, as compared to a 4-
month PFS of only 18 % for HGS. Of note, all pediatric
patients had a diagnosis of classic osteosarcoma. These
findings were confirmed in terms of response rate, with
partial responses observed only in patients with high-
grade osteosarcoma, whereas no objective response was
seen in the HGS cohort, suggesting that patients with re-
current HGS should be offered participation in clinical
trials of novel agents.
The PFS observed in the present series (46 % at
4 months) is superior to the 4-month PFS value of 40 %,
the threshold to identify active agents in advanced soft
tissue sarcomas set by Van Glabbeke and colleagues
[19]. It is also superior to the PFS of a similar group of
patients treated in a prospective Phase II study with
pemetrexed (3-month PFS 17.2 % (95 % CI: 3.5–31) [7],
and equivalent to that of sorafenib (4-month PFS 46 %)
and sorafenib + everolimus combination (4-month PFS >
55 %) [8, 9].
Table 3 Grade 3-4 non-hemathologic toxicity in 51 patient receiving gemcitabine and docetaxel (GD)
G3-4 non-hemathologic toxicity Compliance Outcome GD cys
Allergic reaction (1st cycle) Stop docetaxel Resolved 2
Allergic reaction (1st cycle) Stop docetaxel Resolved 4
Allergic reaction (4th cycle) Stop docetaxel Resolved 5
Capillary leak syndrome Stop docetaxel Resolved 9
Diarrhea Delay/dose reduction Resolved 6
Febrile neutropenia Delay Resolved 7
Lung fibrosis None Resolved 5
Foot syndrome None Resolved 2
Stephen Johnson syndrome Stop docetaxel Off -treatment 1
GD cys gemcitabine and docetaxel number of chemoteherapy cycles
Table 4 Responses according to histology in 46 patients with
measurable disease by RECIST
Osteosarcoma (n = 35) n (%) HGS (n = 11) n (%) All (46) n (%)
PR 6 (17) 0 6 (13)
SD 14 (40) 6 (55) 20 (43)
PD 15 (43) 5 (45) 20 (43)
HGS High grade spindle cell sarcoma of bone
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The response rate for GD was 13 % (17 % if we ex-
clude HGS). With HDIFO, the treatment of choice in
1st line for metastatic osteosarcoma, response rates de-
scribed range between 10 and 62 % [6, 20, 21], while for
other drugs such as cyclophosphamide and etoposide,
objective responses were seen in 19 % and 28.5 % of pa-
tients respectively in different studies [22, 23]. With so-
rafenib, as monotherapy, or in combination with m-TOR
inhibitors, the response rate is very low (sorafenib: 8 %,
sorafenib + everolimus: 5 %) [8, 9].
There are few published data assessing the activity of
GD in patients with recurrent osteosarcoma. Conflicting
results are reported and most of the studies were based
on a small number of patients (Table 1; [13–18]).
In a study by Song et al., a response rate of 24 % was
described in 17 pediatric patients (3 CR and 1 PR) [18].
The median OS was 9 months (range, 0.6–79.6) [18],
similarly to the median OS of the present study
(7.5 months, range 2–45).
On the contrary, the prospective SARC (Sarcoma Alli-
ance for Research Through Collaboration) study explor-
ing the activity of GD in a group of different bone
sarcomas (including Ewing, chondrosarcoma and 14 pa-
tients with osteosarcoma), demonstrated a lack of activ-
ity in all cohorts, including osteosarcoma [15].
In our series, grade 3–4 neutropenia or thrombocytopenia
was observed in 25 % of the patients, with no differ-
ence according to gemcitabine dose and with only 1
Fig. 2 Progression-free survival curves at 4 months (4-month PFS) in all 51 patients (a) and by histology (b): high-grade osteosarcoma (40 pts)
and high-grade spindle cell sarcoma of bone (HGS; 11 pts)
Table 5 Univariate Analysis of Clinical, Pathologic and
Treatment Variable for PFS in patients with osteosarcoma and
high grade spindle cell sarcoma of bone




≥18 years 23 65 43–88 0.4
<18 years 23 35 17–53
Sex
Female 12 50 22–78 0.7
Male 34 44 27–62
Mets Site
Lung only 24 61 41–81 0.1
Multiple 22 30 11–50
Line GD
2 13 60 32–87 0.4
≥3 33 41 24.58
ECOG
0 29 54 35–72 0.003
1 13 43 15–71
2 4 0 0
Histology
Osteosarcoma 35 56 39–73 0.005
HGS 11 18 0–41
PFS Progression Free Survival, HGS high grade spindle cell sarcoma of bone,
GD gemcitabine and docetaxel
Fig. 3 Progression-free survival curves at 4 months (4-month PFS) in
eight patients rendered macroscopically free of disease following
chemotherapy and metastasectomy (2sCR) versus 4-month PFS in the
remaining 43 patients (no-2CR2); 2sCR: surgical complete remission
Palmerini et al. BMC Cancer  (2016) 16:280 Page 6 of 8
patient with febrile neutropenia, which was described
in about 14 % of cycles after HDIFO [24]. More im-
portantly our study confirms that taxane-related
hypersensitivity reactions (HSR) can be an issue: 3
(6 %) patients experienced allergic reactions during
docetaxel infusion (two following the first cycle and
one after 4 cycles), and were subsequently treated with
gemcitabine monotherapy; in the other 2 pediatric cases,
grade 3 Stephen Johnson syndrome and capillary leak syn-
drome were documented, in one patient each (Table 4).
Taxane-related HSR usually occurs within the first mi-
nutes of infusion in up to 30 % of patients, without pre-
medication, and ≤4 % with antihistamine and steroid
premedication. This is dose and rate-dependent, and ad-
equate premedication and patient monitoring on com-
mencing treatment is recommended [25].
Compared to other therapeutic options in this setting,
we did not observe renal toxicity. This can be an issue
with HDIFO in about 25 % of cases, and in half of these,
irreversible renal failure can occur [24].
Unlike sorafenib, which can cause pneumothorax and
permanent treatment discontinuation in about 3 % of
patients [8, 9], gemcitibine and docetaxel-induced
tumor-shrinkage, was not associated with pneumothorax
in our series.”
Conclusion
In conclusion, there are few new active regimens for pa-
tients with relapsed osteosarcoma following multimodal-
ity therapy [26]. To our knowledge, this is the largest
series of patients treated with GD for relapsed bone sar-
coma published. While a prospective SARC phase II
study showed marginal activity for GD in metastatic
osteosarcoma [15], partly due to limitations in clinical
trial design, as suggested by the authors themselves [15],
we believe that the combination is active and should be
included in the therapeutic armamentarium of meta-
static osteosarcoma.
Abbreviations
CTCAE: Common Toxicity Criteria for Adverse Events; D: docetaxel;
G: gemcitabine; HGS: high-grade spindle cell sarcoma of bone; OS: overall
survival; PD: progressive disease; PFS: progression-free survival; PR: partial
response; RECIST: Response Evaluation Criteria In Solid Tumors; sCR2: surgical
complete response; SD: stable disease.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
EP, RLJ, PP, SF: substantive intellectual contribution to conception and
design of study, drafting and revision of manuscript, statistical analyses and
interpretation of data AP, EM, RLJ, SP, GG, SF: final approval of the version to
be published EP, AP, MC, AL, CM, LC, FF, SA, AT: patients selection/inclusion
All authors have read and approved the contents of this manuscript and
declare that the work is original and has not been submitted or published
elsewhere.
Acknowledgments
This work was supported by: the Associazione Onlus “il Pensatore: Matteo
Amitrano”; 5 ‰ donation (Italy), EU FP7 Eurosarc, Biobanca Oncologia Emilia
Romagna.
Dr E. Pamerini’s work is supported by the Emilia-Romagna Region
HighTechnology Network, PROMETEO Laboratory at Istituto Ortopedico Rizzoli.
We thank Cristina Ghinelli for figures and table editing.
Author details
1PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli,
Bologna, Italy. 2University of Washington/ Fred Hutchinson Cancer Research
Center, Seattle, USA. 3Oncoematologia Pediatrica INT, Milan, Italy. 4UO
Oncoematologia Pediatrica Pisa, Pisa, Italy. 5Oncoematologia Pediatrica
Torino, Torino, Italy. 6IRCCS Candiolo, Torino, Italy. 7Oncoematologia Azienda
Ospedaliera Universitaria Meyer Pediatrica, Firenze, Italy. 8Laboratory
Research, Istituto Ortopedico Rizzoli, Bologna, Italy. 9PROMETEO Laboratory/
Section of Chemotherapy, Research, Innovation & Technology (RIT)
Department, Istituto Ortopedico Rizzoli, Via Pupilli, 1, 40136 Bologna, Italy.
Received: 17 July 2015 Accepted: 13 April 2016
References
1. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination
chemotherapy for osteogenic sarcoma. Curr Opin Oncol. 2007;19:341–6.
2. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade
osteosarcoma of the extremities or trunk: an analysis of 1,702 patients
treated on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 2002;20:776–90.
3. Ferrari S, Briccoli A, Mercuri M, et al. Pos t relapse survival in osteosarcoma
of the extremities: prognostic factors for long-term survival. J Clin Oncol.
2003;21:710–5.
4. ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 2014;25 suppl 3:iii113–23.
5. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform
response of metastases to high dose ifosfamide. Cancer. 1994;73:2506–11.
6. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone
and soft tissue sarcomas: results of phase II and pilot studies–dose–response
and schedule dependence. J Clin Oncol. 1997;15:2378–84.
7. Duffaud F, Egerer G, Ferrari S, et al. A phase II trial of second-line
pemetrexed in adults with advanced/metastatic osteosarcoma. Eur J Cancer.
2012;48:564–70.
8. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and
unresectable high-grade osteosarcoma after failure of standard multimodal
therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23:508–16.
9. Grignani G, Palmerini E, Ferraresi V, Italian Sarcoma Group, et al. Sorafenib
and everolimus for patients with unresectable high-grade osteosarcoma
progressing after standard treatment: a non-randomised phase 2 clinical
trial. Lancet Oncol. 2015;16:98–107.
10. Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified
phase II study of gemcitabine alone versus gemcitabine and docetaxel in
patients with metastatic or relapsed leiomyosarcomas: a Federation
Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma
Group Study (TAXOGEM study). Oncologist. 2012;17:1213–20.
11. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of
gemcitabine and docetaxel compared with gemcitabine alone in patients
with metastatic soft tissue sarcomas: results of sarcoma alliance for research
through collaboration study 002 [corrected]. J Clin Oncol. 2007;25:2755–63.
12. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in
patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin
Oncol. 2002;20:2824–31.
13. Merimsky O, Meller I, Kollender Y, et al. Gemcitabine in bone sarcoma
resistant to Doxorubicin-based chemotherapy. Sarcoma. 2000;4:7–10.
14. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and
docetaxel in the treatment of children and young adults with refractory
bone sarcoma. Cancer. 2008;113:419–25.
15. Fox E, Patel S, Wathen JK, et al. Phase II study of sequential gemcitabine
followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or
unresectable or locally recurrent chondrosarcoma: results of Sarcoma
Palmerini et al. BMC Cancer  (2016) 16:280 Page 7 of 8
Alliance for Research Through Collaboration Study 003. Oncologist.
2012;17:321.
16. Gosiengfiao Y, Reichek J, Woodman J, et al. Gemcitabine with or without
docetaxel and resection for recurrent osteosarcoma: the experience at
Children's Memorial Hospital. J Pediatr Hematol Oncol. 2012;34:e63–5.
17. He AN, Tang LN, Shen Z, et al. Efficacy and safety of gemcitabine-docetaxel
combination therapy for recurrent or refractory high-grade osteosarcoma in
China: a retrospective study of 18 patients. Jpn J Clin Oncol. 2012;42:427–31.
18. Song BS, Seo J, Kim DH, et al. Gemcitabine and docetaxel for the treatment
of children and adolescents with recurrent or refractory osteosarcoma:
Korea Cancer Center Hospital experience. Pediatr Blood Cancer. 2014;61:
1376–81.
19. Van Glabbeke M, Verweij J, Judson I, EORTC Soft Tissue and BoneSarcoma
Group, et al. Progression-free rate as the principal end-point for phase II
trials insoft-tissue sarcomas. Eur J Cancer. 2002;38:543–9.
20. Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with
ifosfamide: comparison of response in pediatric patients with recurrent
disease versus patients previously untreated: a PediatricOncology Group
study. Med Pediatr Oncol. 1995;24(2):87–92.
21. Lee SH, Chang MH, Baek KK, et al. High-dose ifosfamide as second- or
third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Oncology. 2011;80(3-4):257-61.
22. Berger M, Grignani G, Ferrari S, et al. Phase 2 trial of two courses of
cyclophosphamide and etoposide for relapsed high-risk osteosarcoma
patients. Cancer. 2009;115:2980–7.
23. Rodríguez-Galindo C, Daw NC, Kaste SC, et al. Treatment of refractory
osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr
Hematol Oncol. 2002;24:250–5.
24. Berrak SG, Pearson M, Berberoğlu S, Ilhan IE, Jaffe N. High-dose ifosfamide in
relapsed pediatric osteosarcoma: therapeutic effects and renal toxicit.
Pediatr Blood Cancer. 2005;44(3):215–9.
25. Joerger M. Prevention and handling of acute allergic and infusion reactions
in oncology. Ann Oncol. 2012;23 Suppl 10:x313.
26. Benjamin RS. Osteosarcoma: better treatment through better trial design.
Lancet Oncol. 2015;16:12–3.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Palmerini et al. BMC Cancer  (2016) 16:280 Page 8 of 8
